Overview

Maximal Bruce Protocol With the Use of Regadenoson For Myocardial Perfusion Stress Testing

Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
It is been known for at least 20 years that the hemodynamic data, the amount of exercise performed as well as symptoms on the treadmill, has significant value to the perfusion stress testing. When a pharmacologic stress test is performed (and adenosine stress test over 4-6 minutes), this hemodynamic data is lost. Because of this loss of valuable data, it is felt that there is also a loss of significant prognostic data as well. With the advent and FDA release of Regadenoson in a rapid injection form (over 10 seconds), it is thought that the combination of both exercise stress testing and pharmacologic testing in subjects that do not achieve 85% in a maximal predicted heart rate may be a viable stress testing option. The purpose of this study is to look at using the drug, regadenoson, with exercise stress testing; and the side effect symptoms that may be experienced by individual subjects using this combination.
Phase:
N/A
Details
Lead Sponsor:
University of Maryland
University of Maryland, Baltimore
Collaborator:
Astellas Pharma US, Inc.
Treatments:
Regadenoson